Immunosuppressive agents in adult kidney transplantation in the NHS: a model-based economic evaluation

1 Immunosuppressive agents in adult kidney transplantation in the NHS: a model-based economic evaluation Tristan Snowsill, Jason Moore, Ruben Mujica Mota, Jaime Peters, Tracey Jones-Hughes, Nicola Huxley, Helen Coelho, Marcela Haasova, Chris Cooper, Jenny Lowe, Jo Varley-Campbell, Louise Crathorne, Matt Allwood, Rob Anderson Corresponding author: Tristan Snowsill South Cloisters, St Luke’s Campus, Heavitree Road, Exeter EX1 2LU Tel: 0 (+44) 1392 726092 Email: t.m.snowsill@exeter.ac.uk

[1]  R. Mújica-Mota,et al.  Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model. , 2016, Health technology assessment.

[2]  A Gray,et al.  The impact of diabetes‐related complications on healthcare costs: new results from the UKPDS (UKPDS 84) , 2015, Diabetic medicine : a journal of the British Diabetic Association.

[3]  M. Cowie.  National Institute for Health and Care Excellence. , 2015, European heart journal.

[4]  Karl Claxton,et al.  The Value of Heterogeneity for Cost-Effectiveness Subgroup Analysis , 2014, Medical decision making : an international journal of the Society for Medical Decision Making.

[5]  Andrew H Briggs,et al.  Projecting long-term graft and patient survival after transplantation. , 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[6]  I. Macphee,et al.  UK Renal Registry 16th Annual Report: Chapter 3 Demographic and Biochemistry Profile of Kidney Transplant Recipients in the UK in 2012: National and Centre-specific Analyses , 2014, Nephron Clinical Practice.

[7]  D. Fogarty,et al.  UK Renal Registry 14th Annual Report: Chapter 2 UK RRT Prevalence in 2010: National and Centre-Specific Analyses , 2016 .

[8]  M. Schnitzler,et al.  Health‐related quality of life in kidney transplant patients with diabetes , 2013, Clinical transplantation.

[9]  R. Marcén,et al.  Immunosuppressive Drugs in Kidney Transplantation , 2009, Drugs.

[10]  J. Brazier,et al.  Populating an economic model with health state utility values: moving toward better practice. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[11]  J. Bosch,et al.  Preference-based quality of life of patients on renal replacement therapy: a systematic review and meta-analysis. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[12]  J. Gill,et al.  Impact of acute rejection and new-onset diabetes on long-term transplant graft and patient survival. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[13]  D. Brennan,et al.  Rabbit antithymocyte globulin versus basiliximab in renal transplantation. , 2006, The New England journal of medicine.

[14]  D. Quinton,et al.  Unit Costs of Health and Social Care 2004 , 2004 .

[15]  D. Abramowicz,et al.  Prevalence and Management of Anemia in Renal Transplant Recipients: A European Survey , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[16]  J. Squifflet,et al.  A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients1 , 2003, Transplantation.

[17]  A. Laupacis,et al.  A study of the quality of life and cost-utility of renal transplantation. , 1996, Kidney international.